[go: up one dir, main page]

AU2003206945A1 - Use of proteinase inhibitors in the treatment of autoimmune diseases - Google Patents

Use of proteinase inhibitors in the treatment of autoimmune diseases

Info

Publication number
AU2003206945A1
AU2003206945A1 AU2003206945A AU2003206945A AU2003206945A1 AU 2003206945 A1 AU2003206945 A1 AU 2003206945A1 AU 2003206945 A AU2003206945 A AU 2003206945A AU 2003206945 A AU2003206945 A AU 2003206945A AU 2003206945 A1 AU2003206945 A1 AU 2003206945A1
Authority
AU
Australia
Prior art keywords
treatment
autoimmune diseases
proteinase inhibitors
proteinase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003206945A
Other versions
AU2003206945A8 (en
Inventor
Robert Huber
Uwe Jacob
Peter Sondermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10241411A external-priority patent/DE10241411A1/en
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften
Publication of AU2003206945A8 publication Critical patent/AU2003206945A8/en
Publication of AU2003206945A1 publication Critical patent/AU2003206945A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003206945A 2002-02-22 2003-02-21 Use of proteinase inhibitors in the treatment of autoimmune diseases Abandoned AU2003206945A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10207744 2002-02-22
DE10207744.4 2002-02-22
DE10241411A DE10241411A1 (en) 2002-02-22 2002-09-06 Use of proteinase inhibitors for the treatment of autoimmune diseases
DE10241411.4 2002-09-06
PCT/EP2003/001807 WO2003070229A2 (en) 2002-02-22 2003-02-21 Use of proteinase inhibitors in the treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
AU2003206945A8 AU2003206945A8 (en) 2003-09-09
AU2003206945A1 true AU2003206945A1 (en) 2003-09-09

Family

ID=27758411

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003206945A Abandoned AU2003206945A1 (en) 2002-02-22 2003-02-21 Use of proteinase inhibitors in the treatment of autoimmune diseases

Country Status (2)

Country Link
AU (1) AU2003206945A1 (en)
WO (1) WO2003070229A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4898091B2 (en) 2002-03-11 2012-03-14 ザ メディシンズ カンパニー （ライプツィヒ） ゲーエムベーハー Inhibitors of urokinase, their production and use
DE10301300B4 (en) * 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Use of acylated 4-amidino- and 4-guanidinobenzylamines for the inhibition of plasma kallikrein
DE10322191B4 (en) 2003-05-16 2014-02-27 The Medicines Company (Leipzig) Gmbh N-sulfonylated amino acid derivatives, process for their preparation and their use
DE10342108A1 (en) 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basic substituted benzylamine analogs as coagulation factor Xa inhibitors, their preparation and use
CA2620683A1 (en) * 2005-08-29 2007-03-08 Wilex Ag Oxadiazole compounds as urokinase inhibitors
DE102006050672A1 (en) * 2006-10-24 2008-04-30 Curacyte Discovery Gmbh New glycylglycine derivatives with a benzylsulfonylamido group and an amidino-organylamido group at the opposite chain ends, used in drugs for reducing loss of blood, e.g. in operations
US20120172375A1 (en) * 2008-11-07 2012-07-05 Bruce Trapp Compounds and methods of promoting oligodendrocyte precursor differentiation
ES2483802T3 (en) 2010-07-07 2014-08-07 The Medicines Company (Leipzig) Gmbh Serine protease inhibitors
DE102011108346A1 (en) * 2011-07-25 2013-01-31 Philipps-Universität Marburg Use of inhibitors of TMPRSS2 as a drug
US11130780B2 (en) 2015-03-09 2021-09-28 Washington University Inhibitors of growth factor activation enzymes
CN110785172A (en) * 2017-07-21 2020-02-11 红山生物医药有限公司 WX-UK1 and use of WX-671 product thereof for treating non-cancerous medical conditions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843905A (en) * 1993-06-04 1998-12-01 Vertex Pharmaceuticals, Incorporated Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors
MX9705970A (en) * 1995-02-10 1997-11-29 Basf Ag THROMBIN INHIBITORS.
US5834487A (en) * 1996-09-24 1998-11-10 Cv Therapeutics Inhibition of 26S and 20S proteasome by indanones
BR0009678A (en) * 1999-04-09 2002-01-22 Basf Ag Compounds, pharmaceutical composition, and use of compounds
US6358928B1 (en) * 1999-11-22 2002-03-19 Enzyme Systems Products Peptidyl sulfonyl imidazolides as selective inhibitors of serine proteases
FR2819254B1 (en) * 2001-01-08 2003-04-18 Fournier Lab Sa NOVEL N- (PHENYLSULFONYL) GLYCINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR OBTAINING PHARMACEUTICAL COMPOSITIONS
JP2005508979A (en) * 2001-10-29 2005-04-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Compounds useful as reversible inhibitors of cysteine proteases

Also Published As

Publication number Publication date
WO2003070229A2 (en) 2003-08-28
WO2003070229A3 (en) 2004-03-04
AU2003206945A8 (en) 2003-09-09

Similar Documents

Publication Publication Date Title
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
IL164211A0 (en) Il-18 inhibitors and peripheral vascular diseases
AU2003239568A1 (en) Pyrrolotriazinone compounds and their use to treat diseases
AU2003275311A1 (en) Solid micro-perforators and methods of use
AU2003233495A1 (en) Universal-tagged oligonucleotide primers and methods of use
AU2003212323A1 (en) Benzodiazepine-substituted piperidines for utilization in the treatment of cardiovascular diseases
IL166377A0 (en) Vrgfr-2 and vgefr-3 inhibitory and anthranylamidpyrimidines
IL162678A0 (en) N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases
ZA200410409B (en) Use of thio-oxindole derivatives in treatment of hormonerelated conditions
AU2003249645A1 (en) METHODS FOR THE IDENTIFICATION OF IKKAlpha FUNCTION AND OTHER GENES USEFUL FOR TREATMENT OF INFLAMMATORY DISEASES
AU2003293099A1 (en) Treatment of dna damage related disorders
AU2003206945A1 (en) Use of proteinase inhibitors in the treatment of autoimmune diseases
AU2003260778A1 (en) Treatment of pipes
AU2002309180A1 (en) Composition and kit for the treatment of inflammatory bowel diseases
AU2003258942A1 (en) Imidazolidinedione-derivatives and their use as metalloproteinase inhibitors
AU2003287802A1 (en) Palpometer and methods of use thereof
AU2003222250A1 (en) Treatment of autoimmune diseases
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
AU2003293500A1 (en) Lactoferrin in the reduction of pain
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2003283938A1 (en) Use of certain compounds in treatment of obesity
AU2003270615A1 (en) Treatment of steatosis using hyperthermia
AU2003240446A1 (en) Use of mob-5 in pain
AU2003207315A1 (en) Treatment of muscle damage
AU2003256289A1 (en) Modified shine-dalgarno sequences and methods of use thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase